These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
242 related articles for article (PubMed ID: 8436258)
21. Lipoprotein (a) and microvascular disease in type 1 (insulin-dependent) diabetes. Winocour PH; Bhatnagar D; Ishola M; Arrol S; Durrington PN Diabet Med; 1991 Dec; 8(10):922-7. PubMed ID: 1838043 [TBL] [Abstract][Full Text] [Related]
22. Clinical Features and Microvascular Complications Risk Factors of Early-onset Type 2 Diabetes Mellitus. Huang JX; Liao YF; Li YM Curr Med Sci; 2019 Oct; 39(5):754-758. PubMed ID: 31612393 [TBL] [Abstract][Full Text] [Related]
24. Associations and interactions between lipid profiles, retinopathy and nephropathy in patients with type 1 diabetes: the FinnDiane Study. Tolonen N; Hietala K; Forsblom C; Harjutsalo V; Mäkinen VP; Kytö J; Summanen PA; Thorn LM; Wadén J; Gordin D; Taskinen MR; Groop PH; J Intern Med; 2013 Nov; 274(5):469-79. PubMed ID: 23844944 [TBL] [Abstract][Full Text] [Related]
25. Glycemic control, dyslipidemia and endothelial dysfunction in coexisted diabetes, hypertension and nephropathy. Shahid SM; Nawab SN; Shaikh R; Mahboob T Pak J Pharm Sci; 2012 Jan; 25(1):123-9. PubMed ID: 22186319 [TBL] [Abstract][Full Text] [Related]
26. The course of kidney function in type 2 (non-insulin-dependent) diabetic patients with diabetic nephropathy. Gall MA; Nielsen FS; Smidt UM; Parving HH Diabetologia; 1993 Oct; 36(10):1071-8. PubMed ID: 8243857 [TBL] [Abstract][Full Text] [Related]
27. The impact of serum lipids on risk for microangiopathy in patients with type 2 diabetes mellitus. Toth PP; Simko RJ; Palli SR; Koselleck D; Quimbo RA; Cziraky MJ Cardiovasc Diabetol; 2012 Sep; 11():109. PubMed ID: 22978715 [TBL] [Abstract][Full Text] [Related]
28. Relationship between lipoprotein profile and urinary albumin excretion in type II diabetic patients with stable metabolic control. Reverter JL; Sentí M; Rubiés-Prat J; Lucas A; Salinas I; Pizarro E; Pedro-Botet J; Romero R; Sanmartí A Diabetes Care; 1994 Mar; 17(3):189-94. PubMed ID: 8174446 [TBL] [Abstract][Full Text] [Related]
29. The relation between plasma endothelin-1 levels and metabolic control, risk factors, treatment modalities, and diabetic microangiopathy in patients with Type 2 diabetes mellitus. Ak G; Buyukberber S; Sevinc A; Turk HM; Ates M; Sari R; Savli H; Cigli A J Diabetes Complications; 2001; 15(3):150-7. PubMed ID: 11358684 [TBL] [Abstract][Full Text] [Related]
30. Urinary albumin excretion is correlated to fibrinogen levels and protein S activity in patients with type 1 diabetes mellitus without overt diabetic nephropathy. Lengyel Z; Vörös P; Tóth LK; Németh C; Kammerer L; Mihály M; Tornóci L; Rosivall L Wien Klin Wochenschr; 2004 Apr; 116(7-8):240-5. PubMed ID: 15143863 [TBL] [Abstract][Full Text] [Related]
31. Serum triglycerides are a predictive factor for the development and the progression of renal and retinal complications in patients with type 1 diabetes. Hadjadj S; Duly-Bouhanick B; Bekherraz A; BrIdoux F; Gallois Y; Mauco G; Ebran J; Marre M Diabetes Metab; 2004 Feb; 30(1):43-51. PubMed ID: 15029097 [TBL] [Abstract][Full Text] [Related]
32. Is glycation of low density lipoproteins in patients with Type 2 diabetes mellitus a LDL pre-oxidative condition? Moro E; Alessandrini P; Zambon C; Pianetti S; Pais M; Cazzolato G; Bon GB Diabet Med; 1999 Aug; 16(8):663-9. PubMed ID: 10477211 [TBL] [Abstract][Full Text] [Related]
33. Abnormalities in plasmas concentrations of lipoproteins and fibrinogen in type 1 (insulin-dependent) diabetic patients with increased urinary albumin excretion. Jensen T; Stender S; Deckert T Diabetologia; 1988 Mar; 31(3):142-5. PubMed ID: 3371576 [TBL] [Abstract][Full Text] [Related]
34. Correlation between Cystatin C and retinopathy of type-two diabetes mellitus patients. Qian C; Wan GM; Yan PS; Wang WZ; Liang SZ; Dong Y J Biol Regul Homeost Agents; 2017; 31(1):99-103. PubMed ID: 28337877 [TBL] [Abstract][Full Text] [Related]
35. Association between plasma oxidized low-density lipoprotein and diabetic nephropathy. Ujihara N; Sakka Y; Takeda M; Hirayama M; Ishii A; Tomonaga O; Babazono T; Takahashi C; Yamashita K; Iwamoto Y Diabetes Res Clin Pract; 2002 Nov; 58(2):109-14. PubMed ID: 12213352 [TBL] [Abstract][Full Text] [Related]
36. Effects of Vitamin E on susceptibility of low-density lipoprotein and low-density lipoprotein subfractions to oxidation and on protein glycation in NIDDM. Reaven PD; Herold DA; Barnett J; Edelman S Diabetes Care; 1995 Jun; 18(6):807-16. PubMed ID: 7555507 [TBL] [Abstract][Full Text] [Related]
37. Association between serum levels of soluble receptor for advanced glycation end products and circulating advanced glycation end products in type 2 diabetes. Tan KC; Shiu SW; Chow WS; Leng L; Bucala R; Betteridge DJ Diabetologia; 2006 Nov; 49(11):2756-62. PubMed ID: 16969649 [TBL] [Abstract][Full Text] [Related]
38. Advanced glycation end products in adolescents and young adults with diabetic angiopathy. Chiarelli F; Catino M; Tumini S; Cipollone F; Mezzetti A; Vanelli M; Verrotti A Pediatr Nephrol; 2000 Aug; 14(8-9):841-6. PubMed ID: 10955941 [TBL] [Abstract][Full Text] [Related]